Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

Completed · Phase 1 · Has a placebo group

Conditions studied: Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease

In brief

The investigator's hypothesis is that local activation of the endogenous Lp-PLA2 plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, the investigators study will characterize prospectively the correlation between the functional and structural vascular wall properties, and the activity of the Lp-PLA2 pathway.

Key facts

Study ID: NCT01642173
Run by: Mayo Clinic
People needed: 41
Starts: 2010-10-01
Expected to finish: 2015-06-01
Last updated by the study team: 2016-10-03

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

age > 18 years and < 85 years
referred to our cardiac catheterization laboratory for coronary vasomotion testing
are found to have coronary endothelial dysfunction.

You may not qualify if…

these include heart failure
ejection fraction < 40%
unstable angina
myocardial infarction or angioplasty within 6 months prior to entry into the study
use of investigational agents within 1 month of entry into the study,
patients who require treatment with positive inotropic agents other than digoxin during the study
patients with cerebrovascular accident within 6 months prior to entry the study
significant endocrine, hepatic or renal, disorders
local or systemic infectious disease within 4 weeks prior to entry into study
pregnancy or lactation
mental instability
Federal Medical Center inmates

Where it is running

Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.